Table 1 Patient characteristics
Variables | No. of patients (%) (n = 302) |
|---|---|
Age, years, median (range) | 63 (37–90) |
Sex | |
 Male | 231 (76.5) |
 Female | 71 (23.5) |
ECOG performance status | |
 0 | 281 (93.0) |
 1–2 | 21 (7.0) |
Child-Pugh classification | |
 A | 276 (91.4) |
 B | 26 (8.6) |
Viral etiology | |
 Hepatitis B virus | 230 (76.2) |
 Hepatitis C virus | 36 (11.9) |
 Non B, Non C | 36 (11.9) |
BCLC stage | |
 0 | 137 (45.4) |
 A | 165 (54.6) |
Tumor multiplicity at the last TACE | |
 Single | 80 (26.5) |
 Multiple | 222 (73.5) |
Tumor size, cm, median (range) | 2.0 (0.7–6.9) |
Alpha-fetoproteina, median (IQR) | 9.2 (4.1–32.6) |
 ≤ 20 ng/mL | 203 (67.4) |
 >  20 ng/mL | 98 (32.5) |
Number of prior treatment sessions, median (IQR) | 3 (1–5) |
Prior treatments | |
 TACE only | 159 (52.6) |
 TACE, RFA | 60 (19.9) |
 TACE, PEI | 2 (0.7) |
 TACE, RFA, PEI | 8 (2.6) |
 Resection, TACE | 46 (15.2) |
 Resection, TACE, RFA | 25 (8.3) |
 Resection, TACE, PEI | 2 (0.7) |
Fractionation regimen, BED | |
 36 Gy/3fx (80 Gy10) | 16 (5.3) |
 45 Gy/3fx (113 Gy10) | 267 (88.4) |
 48 Gy/3fx (125 Gy10) | 2 (0.7) |
 60 Gy/4fx (150 Gy10) | 16 (5.3) |
 60 Gy/3fx (180 Gy10) | 1 (0.3) |